BLLN
BLLN
US0901681058
BillionToOne, Inc.
Loading chart...

Company Profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Latest News

Related stocks

SHC
SHC • United States
Sotera Health Company
18.06 USD
5.15B USD 1Y +11.4%
ADPT
ADPT • United States
Adaptive Biotechnologies Corpor
26.49 USD
4.23B USD 1Y +67.8%
RDNT
RDNT • United States
RadNet, Inc.
70.91 USD
5.58B USD 1Y -10.3%
VCYT
VCYT • United States
Veracyte, Inc.
45.23 USD
3.64B USD 1Y +24.2%
GRAL
GRAL • United States
GRAIL, Inc.
140.58 USD
6.28B USD 1Y +82.2%
CDNA
CDNA • United States
CareDx, Inc.
63.67 USD
3.29B USD 1Y +320.6%
NEO
NEO • United States
NeoGenomics, Inc.
16.35 USD
2.13B USD 1Y +74.7%
WGS
WGS • United States
GeneDx Holdings Corp.
67.33 USD
2.01B USD 1Y -44.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 155.7 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende